Innovator’s Pitch Challenge

Interested in Connecting? Please contact:
Kazuhiko Tawara
Vice President, Business Development
kazuhiko.tawara@kortuc.com

Message the company or request a 1:1 meeting here

Company Description

We are a clinical stage oncology company developing a radiosensitizer, KORTUC, to improve the efficacy of the radiotherapy (RT) for cancer treatment. We also see a large opportunity in combination of immunotherapy with KORTUC/RT. KORTUC eliminates hypoxia (low level of oxygen) in cancer tumors, which is a fundamental problem in the cancer treatments. KORTUC has been used for more than 1,000 patients in Japan in a variety of solid tumors and demonstrated its safety and efficacy. On top to the ongoing pivotal P2 in the UK for breast cancer, new trials will start for cervical and rectal cancers in the US/EU. We expect to launch our product for the three indications in EU/US in 2026/27. Addressable market for the three indications in EU/US is about 100 thousand patients and the addressable market for additional 6 indications will be as large as 1.5 millions of patients/year globally. We have raised USD 17 million in 2021 and are looking for additional USD 40 million to cover our activities for the next three years.

Pitch Deck

Executive Summary

Pitch Video